Maria Löfgren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Löfgren has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Emilia Svala
Department of Biomedical Sciences and Veterinary Public Health Swedish University of Agricultural Sciences Uppsala Sweden
5 shared publications- Eva Skiöldebrand
Swedish University of Agricultural Sciences, SE-750 07 Uppsala, Sweden
5 shared publications Stina Ekman
Department of Biomedical Sciences and Veterinary Public Health Swedish University of Agricultural Sciences Uppsala Sweden
5 shared publications- Anders Lindahl
University of Gothenburg
3 shared publications - Eva Tydén
Department of Animal Biosciences Swedish University of Agriculture Uppsala Sweden
3 shared publications Anders Lindahl
Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine Sahlgrenska University Hospital, Gothenburg University Gothenburg Sweden
2 shared publications
Latest Publications
- Open Access
- 31 May 2024
- Published by Wiley in Journal of Separation Science
- Vol. 47 (11) , 2400092
Identity verification of monoclonal antibodies by triple injection capillary zone electrophoresis
This paper presents an approach based on triple injection capillary zone electrophoresis for identification of monoclonal antibodies. The analyte to be identified is injected between two zones of a known reference. The distances between the reference zones (plug I and III) and the target zone (plug II) are adjusted by partial electrophoresis of the first and second injection plugs. The full migration time of the target analyte is calculated from the observed migration time by considering the migration times of the reference in the first and third injection plugs. The relative migration time, that is, the ratio between the full migration time of the analyte and the migration time of the reference in the third injection plug provides the basis for identification. Here, eight monoclonal antibodies, including a pair of biosimilars, were used interchangeably as both analyte and reference to investigate potential of the method. The relative migration time for a preliminary positive identification were found to vary between 0.994 and 1.006 (1.000 ± 0.006, p = 95%). Beside the relative migration time, isoform distribution, peak profiles, and early migrating peaks, originating from components in the pharmaceutical formulations, were successfully used to verify the identity of all tested monoclonal antibodies.
- 31 May 2024
- Published by Wiley in Journal of Separation Science
- Vol. 47 (11) , 2400092
Open AccessIdentity verification of monoclonal antibodies by triple injection capillary zone electrophoresis
This paper presents an approach based on triple injection capillary zone electrophoresis for identification of monoclonal antibodies. The analyte to be identified is injected between two zones of a known reference. The distances between the reference zones (plug I and III) and the target zone (plug II) are adjusted by partial electrophoresis of the first and second injection plugs. The full migration time of the target analyte is calculated from the observed migration time by considering the migration times of the reference in the first and third injection plugs. The relative migration time, that is, the ratio between the full migration time of the analyte and the migration time of the reference in the third injection plug provides the basis for identification. Here, eight monoclonal antibodies, including a pair of biosimilars, were used interchangeably as both analyte and reference to investigate potential of the method. The relative migration time for a preliminary positive identification were found to vary between 0.994 and 1.006 (1.000 ± 0.006, p = 95%). Beside the relative migration time, isoform distribution, peak profiles, and early migrating peaks, originating from components in the pharmaceutical formulations, were successfully used to verify the identity of all tested monoclonal antibodies.
- Open Access
- 6 June 2022
- Published by Wiley in Equine Veterinary Journal
- Vol. 55 (2) , 325-335
Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants
Background: Autologous conditioned serum (ACS) is used to treat osteoarthritis in horses, although its effects are not fully investigated.Objectives: To investigate the effects of equine serum and conditioned serum on chondrocytes stimulated with interleukin (IL)‐1β and cartilage explants with mild osteoarthritis.Study design: In vitro experimental study.Methods: The effect of three different serum preparations (unincubated control [PS], serum incubated 24 h [PS24h] and serum incubated 24 h in ACS containers [PCS]) pooled from lame horses were tested in two in vitro models. IL‐1β and IL‐1 receptor antagonist (IL‐1Ra) concentrations were measured in all sera. In model 1, chondrocyte pellet cultures were stimulated with IL‐1β prior to treatment with the serum preparations for 2 and 48 h. Microarray, polymerase chain reaction, and matrix metallopeptidase‐13 analyses were performed. In model 2, cartilage explants from horses with structural osteoarthritis were treated with PS or PCS on days 0, 6 and 12, or left untreated, and evaluated at day 24 using the OARSI grading scale for histological evaluation of articular cartilage.Results: The IL‐1Ra concentration in PS24h and PCS was significantly higher than in PS. In model 1, inflammation‐ and cartilage matrix degradation‐related genes were upregulated after 48 h in all treatment groups versus untreated controls. Cartilage matrix molecules, aggrecan and collagens, were downregulated in PS24h‐ and PCS‐treated pellets versus untreated controls. Growth factor signalling genes were upregulated—FGF7 in all treatment groups, BMP2 in PS24h‐, and INHBA in PCS‐treated—compared with untreated controls. In model 2, the OARSI score at day 24 was not significantly different between treatment groups.Main limitations: Results from in vitro models cannot be directly translated to in vivo situations.Conclusions: In vitro treatment with conditioned serum did not alleviate IL‐1β‐induced responses in chondrocyte pellets or lead to morphological improvement in osteoarthritic cartilage explants.
- 6 June 2022
- Published by Wiley in Equine Veterinary Journal
- Vol. 55 (2) , 325-335
Open AccessConditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants
Background: Autologous conditioned serum (ACS) is used to treat osteoarthritis in horses, although its effects are not fully investigated.Objectives: To investigate the effects of equine serum and conditioned serum on chondrocytes stimulated with interleukin (IL)‐1β and cartilage explants with mild osteoarthritis.Study design: In vitro experimental study.Methods: The effect of three different serum preparations (unincubated control [PS], serum incubated 24 h [PS24h] and serum incubated 24 h in ACS containers [PCS]) pooled from lame horses were tested in two in vitro models. IL‐1β and IL‐1 receptor antagonist (IL‐1Ra) concentrations were measured in all sera. In model 1, chondrocyte pellet cultures were stimulated with IL‐1β prior to treatment with the serum preparations for 2 and 48 h. Microarray, polymerase chain reaction, and matrix metallopeptidase‐13 analyses were performed. In model 2, cartilage explants from horses with structural osteoarthritis were treated with PS or PCS on days 0, 6 and 12, or left untreated, and evaluated at day 24 using the OARSI grading scale for histological evaluation of articular cartilage.Results: The IL‐1Ra concentration in PS24h and PCS was significantly higher than in PS. In model 1, inflammation‐ and cartilage matrix degradation‐related genes were upregulated after 48 h in all treatment groups versus untreated controls. Cartilage matrix molecules, aggrecan and collagens, were downregulated in PS24h‐ and PCS‐treated pellets versus untreated controls. Growth factor signalling genes were upregulated—FGF7 in all treatment groups, BMP2 in PS24h‐, and INHBA in PCS‐treated—compared with untreated controls. In model 2, the OARSI score at day 24 was not significantly different between treatment groups.Main limitations: Results from in vitro models cannot be directly translated to in vivo situations.Conclusions: In vitro treatment with conditioned serum did not alleviate IL‐1β‐induced responses in chondrocyte pellets or lead to morphological improvement in osteoarthritic cartilage explants.
- 29 April 2022
- Published by Wiley in Equine Veterinary Journal
Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants
Autologous conditioned serum (ACS) is used to treat osteoarthritis in horses, although its effects are not fully investigated. To investigate the effects of equine serum and conditioned serum on chondrocytes stimulated with interleukin (IL)-1β and cartilage explants with mild osteoarthritis. In vitro experimental study. The effect of three different serum preparations (unincubated control [PS], serum incubated 24 h [PS24h], and serum incubated 24 h in ACS containers [PCS]) pooled from lame horses were tested in two in vitro models. IL-1β and IL-1 receptor antagonist (IL-1Ra) concentrations were measured in all sera. In model 1, chondrocyte pellet cultures were stimulated with IL-1β prior to treatment with the serum preparations for 2 and 48 h. Microarray, polymerase chain reaction, and matrix metallopeptidase-13 analyses were performed. In model 2, cartilage explants from horses with structural osteoarthritis were treated with PS or PCS on days 0, 6, and 12, or left untreated, and evaluated at day 24 using the OARSI grading scale for histological evaluation of articular cartilage. The IL-1Ra concentration in PS24h and PCS was significantly higher than in PS. In model 1, inflammation- and cartilage matrix degradation-related genes were upregulated after 48 h in all treatment groups versus untreated controls. Cartilage matrix molecules, aggrecan and collagens, were downregulated in PS24h- and PCS- treated pellets versus untreated controls. Growth factor signalling genes were upregulated-FGF7 in all treatment groups, BMP2 in PS24h-, and INHBA in PCS-treated- compared with untreated controls. In model 2, the OARSI score at day 24 was not significantly different between treatment groups. Results from in vitro models cannot be directly translated to in vivo situations. In vitro treatment with conditioned serum did not alleviate IL-1β-induced responses in chondrocyte pellets or lead to morphological improvement in osteoarthritic cartilage explants.
- 29 April 2022
- Published by Wiley in Equine Veterinary Journal
Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants
Autologous conditioned serum (ACS) is used to treat osteoarthritis in horses, although its effects are not fully investigated. To investigate the effects of equine serum and conditioned serum on chondrocytes stimulated with interleukin (IL)-1β and cartilage explants with mild osteoarthritis. In vitro experimental study. The effect of three different serum preparations (unincubated control [PS], serum incubated 24 h [PS24h], and serum incubated 24 h in ACS containers [PCS]) pooled from lame horses were tested in two in vitro models. IL-1β and IL-1 receptor antagonist (IL-1Ra) concentrations were measured in all sera. In model 1, chondrocyte pellet cultures were stimulated with IL-1β prior to treatment with the serum preparations for 2 and 48 h. Microarray, polymerase chain reaction, and matrix metallopeptidase-13 analyses were performed. In model 2, cartilage explants from horses with structural osteoarthritis were treated with PS or PCS on days 0, 6, and 12, or left untreated, and evaluated at day 24 using the OARSI grading scale for histological evaluation of articular cartilage. The IL-1Ra concentration in PS24h and PCS was significantly higher than in PS. In model 1, inflammation- and cartilage matrix degradation-related genes were upregulated after 48 h in all treatment groups versus untreated controls. Cartilage matrix molecules, aggrecan and collagens, were downregulated in PS24h- and PCS- treated pellets versus untreated controls. Growth factor signalling genes were upregulated-FGF7 in all treatment groups, BMP2 in PS24h-, and INHBA in PCS-treated- compared with untreated controls. In model 2, the OARSI score at day 24 was not significantly different between treatment groups. Results from in vitro models cannot be directly translated to in vivo situations. In vitro treatment with conditioned serum did not alleviate IL-1β-induced responses in chondrocyte pellets or lead to morphological improvement in osteoarthritic cartilage explants.
- Open Access
- 13 August 2020
- Published by Wiley in Veterinary Medicine and Science
- Vol. 7 (1) , 16-24
Expression of xenobiotic metabolising enzymes in lungs of horses with or without histological evidence of lower airway inflammation
Mild, moderate and severe equine asthma is a problem for equine welfare. The aetiology of the disease is not known in detail but is likely multi‐factorial. One important factor may be inhaled dust which carries harmful substances which may be bioactivated and thus can lead to local inflammation in the airways. The aim of this study was to investigate gene expression and protein localisation of cytochrome P450 (CYP) enzymes, superoxide dismutase and glutathione‐S‐transferases (GST) involved in bioactivation and detoxification of harmful substances in lungs of horses with or without histological evidence of lower airway inflammation. Significantly lower gene expression of CYP2A13 and GSTM1 was observed in lungs from horses with histological evidence of lower airway inflammation compared with horses without. A higher expression, although not significant, was found for CYP1A1 in horses with histological evidence of lower airway inflammation. There were no differences in gene expression of GSTP1 and SOD3. The proteins were localised in the respiratory epithelium which is of relevance as a defence to local exposure of inhaled harmful substances. In conclusion, our study reports differential gene expression of enzymes involved in bioactivation and detoxification of foreign substances in the lungs of horses with histological evidence of lower airway inflammation compared with horses without.
- 13 August 2020
- Published by Wiley in Veterinary Medicine and Science
- Vol. 7 (1) , 16-24
Open AccessExpression of xenobiotic metabolising enzymes in lungs of horses with or without histological evidence of lower airway inflammation
Mild, moderate and severe equine asthma is a problem for equine welfare. The aetiology of the disease is not known in detail but is likely multi‐factorial. One important factor may be inhaled dust which carries harmful substances which may be bioactivated and thus can lead to local inflammation in the airways. The aim of this study was to investigate gene expression and protein localisation of cytochrome P450 (CYP) enzymes, superoxide dismutase and glutathione‐S‐transferases (GST) involved in bioactivation and detoxification of harmful substances in lungs of horses with or without histological evidence of lower airway inflammation. Significantly lower gene expression of CYP2A13 and GSTM1 was observed in lungs from horses with histological evidence of lower airway inflammation compared with horses without. A higher expression, although not significant, was found for CYP1A1 in horses with histological evidence of lower airway inflammation. There were no differences in gene expression of GSTP1 and SOD3. The proteins were localised in the respiratory epithelium which is of relevance as a defence to local exposure of inhaled harmful substances. In conclusion, our study reports differential gene expression of enzymes involved in bioactivation and detoxification of foreign substances in the lungs of horses with histological evidence of lower airway inflammation compared with horses without.
- Open Access
- 20 June 2019
- Published by Springer Nature in Acta Veterinaria Scandinavica
- Vol. 61 (1) , 1-17
Disposition and effect of intra-articularly administered dexamethasone on lipopolysaccharide induced equine synovitis
Dexamethasone is used for the intra-articular route of administration in management of aseptic arthritis in horses. Despite its widespread use there is very little quantitative data of the disposition and response to dexamethasone. The aim of this study was to investigate and describe the synovial fluid and plasma dexamethasone concentration over time and to explore the relation between synovial fluid concentration and response using clinical endpoints as response biomarkers after IA injection of dexamethasone disodium salt solution in an equine model of synovitis. Inflammation was induced in the radiocarpal joint of six horses by injection of 2 ng lipopolysaccharide (LPS). Two hours later either saline or dexamethasone was injected in the same joint in a two treatment cross over design. Each horse was treated once with one of the six doses dexamethasone used (0.01, 0.03, 0.1, 0.3, 1 or 3 mg) and once with saline. Dexamethasone was quantified by means of UHPLC–MS/MS. Dexamethasone disposition was characterised by means of a non-linear mixed effects model. Lameness was evaluated both objectively with an inertial sensor based system and subjectively scored using a numerical scale (0–5). Joint circumference, skin temperature over the joint and rectal temperature were also recorded. The LPS-challenge induced lameness in all horses with high inter-individual variability. Dexamethasone significantly decreased lameness compared with saline. Other variables were not statistically significant different between treatments. Objective lameness scoring was the most sensitive method used in this study to evaluate the lameness response. A pharmacokinetic/pharmacodynamic model was successfully fitted to experimental dexamethasone and lameness data. The model allowed characterization of the dexamethasone synovial fluid concentration–time course, the systemic exposure to dexamethasone after intra-articular administration and the concentration–response relation in an experimental model of synovitis. The quantitative data improve the understanding of the pharmacology of dexamethasone and might serve as input for future experiments and possibly contribute to maintain integrity of equine sports.
- 20 June 2019
- Published by Springer Nature in Acta Veterinaria Scandinavica
- Vol. 61 (1) , 1-17
Open AccessDisposition and effect of intra-articularly administered dexamethasone on lipopolysaccharide induced equine synovitis
Dexamethasone is used for the intra-articular route of administration in management of aseptic arthritis in horses. Despite its widespread use there is very little quantitative data of the disposition and response to dexamethasone. The aim of this study was to investigate and describe the synovial fluid and plasma dexamethasone concentration over time and to explore the relation between synovial fluid concentration and response using clinical endpoints as response biomarkers after IA injection of dexamethasone disodium salt solution in an equine model of synovitis. Inflammation was induced in the radiocarpal joint of six horses by injection of 2 ng lipopolysaccharide (LPS). Two hours later either saline or dexamethasone was injected in the same joint in a two treatment cross over design. Each horse was treated once with one of the six doses dexamethasone used (0.01, 0.03, 0.1, 0.3, 1 or 3 mg) and once with saline. Dexamethasone was quantified by means of UHPLC–MS/MS. Dexamethasone disposition was characterised by means of a non-linear mixed effects model. Lameness was evaluated both objectively with an inertial sensor based system and subjectively scored using a numerical scale (0–5). Joint circumference, skin temperature over the joint and rectal temperature were also recorded. The LPS-challenge induced lameness in all horses with high inter-individual variability. Dexamethasone significantly decreased lameness compared with saline. Other variables were not statistically significant different between treatments. Objective lameness scoring was the most sensitive method used in this study to evaluate the lameness response. A pharmacokinetic/pharmacodynamic model was successfully fitted to experimental dexamethasone and lameness data. The model allowed characterization of the dexamethasone synovial fluid concentration–time course, the systemic exposure to dexamethasone after intra-articular administration and the concentration–response relation in an experimental model of synovitis. The quantitative data improve the understanding of the pharmacology of dexamethasone and might serve as input for future experiments and possibly contribute to maintain integrity of equine sports.
- 1 June 2018
- Published by Elsevier in Research in Veterinary Science
- Vol. 118, 466-476
Time-dependent changes in gene expression induced in vitro by interleukin-1β in equine articular cartilage
- 1 June 2018
- Published by Elsevier in Research in Veterinary Science
- Vol. 118, 466-476
Time-dependent changes in gene expression induced in vitro by interleukin-1β in equine articular cartilage
- 22 April 2015
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 56 (4) , 315-325
An inflammatory equine model demonstrates dynamic changes of immune response and cartilage matrix molecule degradationin vitro
The molecular aspects of inflammation were investigated in equine articular cartilage explants using quantitative proteomics. Articular cartilage explants were stimulated with interleukin (IL)-1β in vitro for 25 days, and proteins released into cell culture media were chemically labeled with isobaric mass tags and analyzed by liquid chromatography-tandem mass spectrometry. A total of 127 proteins were identified and quantified in media from explants. IL-1β-stimulation resulted in an abundance of proteins related to inflammation, including matrix metalloproteinases, acute phase proteins, complement components and IL-6. Extracellular matrix (ECM) molecules were released at different time points, and fragmentation of aggrecan and cartilage oligomeric matrix protein was observed at days 3 and 6, similar to early-stage OA in vivo. Degradation products of the collagenous network were observed at days 18 and 22, similar to late-stage OA. This model displays a longitudinal quantification of released molecules from the ECM of articular cartilage. Identification of dynamic changes of extracellular matrix molecules in the secretome of equine explants stimulated with IL-1β over time may be useful for identifying components released at different time points during the spontaneous OA process.
- 22 April 2015
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 56 (4) , 315-325
An inflammatory equine model demonstrates dynamic changes of immune response and cartilage matrix molecule degradationin vitro
The molecular aspects of inflammation were investigated in equine articular cartilage explants using quantitative proteomics. Articular cartilage explants were stimulated with interleukin (IL)-1β in vitro for 25 days, and proteins released into cell culture media were chemically labeled with isobaric mass tags and analyzed by liquid chromatography-tandem mass spectrometry. A total of 127 proteins were identified and quantified in media from explants. IL-1β-stimulation resulted in an abundance of proteins related to inflammation, including matrix metalloproteinases, acute phase proteins, complement components and IL-6. Extracellular matrix (ECM) molecules were released at different time points, and fragmentation of aggrecan and cartilage oligomeric matrix protein was observed at days 3 and 6, similar to early-stage OA in vivo. Degradation products of the collagenous network were observed at days 18 and 22, similar to late-stage OA. This model displays a longitudinal quantification of released molecules from the ECM of articular cartilage. Identification of dynamic changes of extracellular matrix molecules in the secretome of equine explants stimulated with IL-1β over time may be useful for identifying components released at different time points during the spontaneous OA process.
- 1 September 2014
- Published by Wiley in Journal of Anatomy
- Vol. 225 (5) , 548-568
Cell and matrix modulation in prenatal and postnatal equine growth cartilage, zones of Ranvier and articular cartilage
Formation of synovial joints includes phenotypic changes of the chondrocytes and the organisation of their extracellular matrix is regulated by different factors and signalling pathways. Increased knowledge of the normal processes involved in joint development may be used to identify similar regulatory mechanisms during pathological conditions in the joint. Samples of the distal radius were collected from prenatal and postnatal equine growth plates, zones of Ranvier and articular cartilage with the aim of identifying Notch signalling components and cells with stem cell‐like characteristics and to follow changes in matrix protein localisation during joint development. The localisation of the Notch signalling components Notch1, Delta4, Hes1, Notch dysregulating protein epidermal growth factor‐like domain 7 (EGFL7), the stem cell‐indicating factor Stro‐1 and the matrix molecules cartilage oligomeric matrix protein (COMP), fibromodulin, matrilin‐1 and chondroadherin were studied using immunohistochemistry. Spatial changes in protein localisations during cartilage maturation were observed for Notch signalling components and matrix molecules, with increased pericellular localisation indicating new synthesis and involvement of these proteins in the formation of the joint. However, it was not possible to characterise the phenotype of the chondrocytes based on their surrounding matrix during normal chondrogenesis. The zone of Ranvier was identified in all horses and characterised as an area expressing Stro‐1, EGFL7 and chondroadherin with an absence of COMP and Notch signalling. Stro‐1 was also present in cells close to the perichondrium, in the articular cartilage and in the fetal resting zone, indicating stem cell‐like characteristics of these cells. The presence of stem cells in the articular cartilage will be of importance for the repair of damaged cartilage. Perivascular chondrocytes and hypertrophic cells of the cartilage bone interface displayed positive staining for EGFL7, which is a novel finding and suggests a role of EGFL7 in the vascular infiltration of growth cartilage.
- 1 September 2014
- Published by Wiley in Journal of Anatomy
- Vol. 225 (5) , 548-568
Cell and matrix modulation in prenatal and postnatal equine growth cartilage, zones of Ranvier and articular cartilage
Formation of synovial joints includes phenotypic changes of the chondrocytes and the organisation of their extracellular matrix is regulated by different factors and signalling pathways. Increased knowledge of the normal processes involved in joint development may be used to identify similar regulatory mechanisms during pathological conditions in the joint. Samples of the distal radius were collected from prenatal and postnatal equine growth plates, zones of Ranvier and articular cartilage with the aim of identifying Notch signalling components and cells with stem cell‐like characteristics and to follow changes in matrix protein localisation during joint development. The localisation of the Notch signalling components Notch1, Delta4, Hes1, Notch dysregulating protein epidermal growth factor‐like domain 7 (EGFL7), the stem cell‐indicating factor Stro‐1 and the matrix molecules cartilage oligomeric matrix protein (COMP), fibromodulin, matrilin‐1 and chondroadherin were studied using immunohistochemistry. Spatial changes in protein localisations during cartilage maturation were observed for Notch signalling components and matrix molecules, with increased pericellular localisation indicating new synthesis and involvement of these proteins in the formation of the joint. However, it was not possible to characterise the phenotype of the chondrocytes based on their surrounding matrix during normal chondrogenesis. The zone of Ranvier was identified in all horses and characterised as an area expressing Stro‐1, EGFL7 and chondroadherin with an absence of COMP and Notch signalling. Stro‐1 was also present in cells close to the perichondrium, in the articular cartilage and in the fetal resting zone, indicating stem cell‐like characteristics of these cells. The presence of stem cells in the articular cartilage will be of importance for the repair of damaged cartilage. Perivascular chondrocytes and hypertrophic cells of the cartilage bone interface displayed positive staining for EGFL7, which is a novel finding and suggests a role of EGFL7 in the vascular infiltration of growth cartilage.
- 12 September 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 36 (4) , 370-375
The genes of all sevenCYP3A isoenzymes identified in the equine genome are expressed in the airways of horses
In the present study, we examined the gene expression of cytochrome P450 3A (CYP3A) isoenzymes in the tracheal and bronchial mucosa and in the lung of equines using TaqMan probes. The results show that all sevenCYP3A isoforms identified in the equine genome, that is,CYP3A89,CYP3A93,CYP3A94,CYP3A95,CYP3A96,CYP3A97 andCYP3A129, are expressed in the airways of the investigated horses. Though in previous studies,CYP3A129 was found to be absent in equine intestinal mucosa and liver, thisCYP3A isoform is expressed in the airways of horses. The gene expression of theCYP3A isoenzymes varied considerably between the individual horses studied. However, in most of the horsesCYP3A89,CYP3A93,CYP3A96,CYP3A97 andCYP3A129 were expressed to a high extent, whileCYP3A94 andCYP3A95 were expressed to a low extent in the different parts of the airways. TheCYP3A isoenzymes present in the airways may play a role in the metabolic degradation of inhaled xenobiotics. In some instances, the metabolism may, however, result in bioactivation of the xenobiotics and subsequent tissue injury.
- 12 September 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 36 (4) , 370-375
The genes of all sevenCYP3A isoenzymes identified in the equine genome are expressed in the airways of horses
In the present study, we examined the gene expression of cytochrome P450 3A (CYP3A) isoenzymes in the tracheal and bronchial mucosa and in the lung of equines using TaqMan probes. The results show that all sevenCYP3A isoforms identified in the equine genome, that is,CYP3A89,CYP3A93,CYP3A94,CYP3A95,CYP3A96,CYP3A97 andCYP3A129, are expressed in the airways of the investigated horses. Though in previous studies,CYP3A129 was found to be absent in equine intestinal mucosa and liver, thisCYP3A isoform is expressed in the airways of horses. The gene expression of theCYP3A isoenzymes varied considerably between the individual horses studied. However, in most of the horsesCYP3A89,CYP3A93,CYP3A96,CYP3A97 andCYP3A129 were expressed to a high extent, whileCYP3A94 andCYP3A95 were expressed to a low extent in the different parts of the airways. TheCYP3A isoenzymes present in the airways may play a role in the metabolic degradation of inhaled xenobiotics. In some instances, the metabolism may, however, result in bioactivation of the xenobiotics and subsequent tissue injury.
- 29 January 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 35 (6) , 588-595
Differential gene expression of CYP3A isoforms in equine liver and intestines
Tydén, E., Löfgren, M., Pegolo, S., Capolongo, F., Tjälve, H., Larsson, P. Differential gene expression of CYP3A isoforms in equine liver and intestines. J. vet. Pharmacol. Therap. 35, 588–595. Recently, seven CYP3A isoforms – CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96, CYP3A97 and CYP129 – have been isolated from the horse genome. In this study, we have examined the hepatic and intestinal gene expression of these CYP3A isoforms using TaqMan probes. We have also studied the enzyme activity using luciferin-isopropyl acetal (LIPA) as a substrate. The results show a differential gene expression of the CYP3A isoforms in the liver and intestines in horses. In the liver, CYP3A89, CYP3A94, CYP3A96 and CYP3A97 were highly expressed, while in the intestine there were only two dominating isoforms, CYP3A93 and CYP3A96. The isoform CYP3A129 was not detected in the liver or the intestine, although this gene consists of a complete set of exons and should therefore code for a functional protein. It is possible that this gene is expressed in tissues other than the liver and intestines. In the intestine, both CYP3A96 and CYP3A93 showed the highest gene expression in the duodenum and the proximal parts of the jejunum. This correlated with a high protein expression in these tissues. Studies of the enzyme activity showed the same Km for the LIPA substrate in the liver and the intestine, while the maximum velocity (Vmax) in the liver was higher than in the intestine. Our finding of a differential gene expression of the CYP3A isoforms in the liver and the intestines contributes to a better understanding of drug metabolism in horses.
- 29 January 2012
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 35 (6) , 588-595
Differential gene expression of CYP3A isoforms in equine liver and intestines
Tydén, E., Löfgren, M., Pegolo, S., Capolongo, F., Tjälve, H., Larsson, P. Differential gene expression of CYP3A isoforms in equine liver and intestines. J. vet. Pharmacol. Therap. 35, 588–595. Recently, seven CYP3A isoforms – CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96, CYP3A97 and CYP129 – have been isolated from the horse genome. In this study, we have examined the hepatic and intestinal gene expression of these CYP3A isoforms using TaqMan probes. We have also studied the enzyme activity using luciferin-isopropyl acetal (LIPA) as a substrate. The results show a differential gene expression of the CYP3A isoforms in the liver and intestines in horses. In the liver, CYP3A89, CYP3A94, CYP3A96 and CYP3A97 were highly expressed, while in the intestine there were only two dominating isoforms, CYP3A93 and CYP3A96. The isoform CYP3A129 was not detected in the liver or the intestine, although this gene consists of a complete set of exons and should therefore code for a functional protein. It is possible that this gene is expressed in tissues other than the liver and intestines. In the intestine, both CYP3A96 and CYP3A93 showed the highest gene expression in the duodenum and the proximal parts of the jejunum. This correlated with a high protein expression in these tissues. Studies of the enzyme activity showed the same Km for the LIPA substrate in the liver and the intestine, while the maximum velocity (Vmax) in the liver was higher than in the intestine. Our finding of a differential gene expression of the CYP3A isoforms in the liver and the intestines contributes to a better understanding of drug metabolism in horses.